| Outcome Measures: |
Primary: Urinary Excretion of Glucose (Measured During the 24 Hours Following Administration of Canagliflozin), The pharmacodynamic response to canagliflozin will be assessed by measuring the increase in 24 hour urinary glucose excretion., 24 hours after administration of canagliflozin|Change in Fractional Excretion of Uric Acid (the Difference Between Data After Administration of Canagliflozin Minus Data Before Administration of Canagliflozin), For the study arm focused on individuals with a genetic variant in SLC2A9, the pharmacodynamic response to canagliflozin will be assessed by measuring the absolute change in fractional excretion of uric acid in the urine. Fractional excretion of uric acid represents the fraction of the calculated filtered uric acid load (serum uric acid level multiplied by the measured creatinine clearance rate) that was excreted in the urine., 24 hour urine collection after administration of canagliflozin | Secondary: Canagliflozin-induced Change in Urinary Excretion of Sodium, The pharmacodynamic response to canagliflozin will be assessed by measuring the % increase in 24 hour urinary excretion of sodium., 24 hours after administration of canagliflozin|Canagliflozin-induced Change in Serum Creatinine, The pharmacodynamic response to canagliflozin will be assessed by measuring changes in serum creatinine, 24 hours after administration of canagliflozin|Canagliflozin-induced Change in Serum Uric Acid, The pharmacodynamic response to canagliflozin will be assessed by measuring changes in serum uric acid level, 24 hours after administration of canagliflozin|Canagliflozin-induced Change in Fasting Plasma Glucose, The magnitude of the change in fasting plasma glucose 24 hours after administration of canagliflozin (300 mg), 24 hrs
|
